Phosphagenics appoints pharma veteran

By Dylan Bushell-Embling
Tuesday, 08 July, 2008

Phosphagenics [ASX: POH] has appointed Michael Ashton to its board as a non-executive director.

Ashton will also act as a consultant on the Melbourne's company's commercialisation strategies.

Ashton has worked for over three decades in the international pharmaceutical industry, including having held senior management positions at Merck, Pfizer and Faulding.

Ashton also served as CEO for SkyePharma PLC.

Scientists uncover how cancer cells hide from immune system

By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Content from other channels on our network

UTS pilot project to mitigate methane emissions

Government invests $1.5m in regional science partnerships

Desalination marine works conclude at Belmont

Zip Water releases 2025 Sustainability Report

Australia's EV fleet transition will be won or lost at the depot

APPEX 2027: The Industry Event Powered by APPMA Returns to Melbourne

From bottleneck to backbone: rethinking water in F&B manufacturing

Barry Callebaut appoints new Chief Operating Officer

Arnott's Group celebrates its suppliers at Sydney event

Record growth for food and grocery manufacturing sector, AFGC reports

Sale of Hobart Private Hospital to Calvary raises concerns

Opinion: The growing risk of AI-driven self-diagnosis in breast health

A new national approach to clinical governance

Opinion: The debate over the government's aged care algorithm is missing the point

Commonwealth Home Support Program extended to 30 June 2029